NEW YORK--(BUSINESS WIRE)--
Levi & Korsinsky announces it has commenced an investigation of Agile Therapeutics, Inc. (AGRX) (“Agile Therapeutics”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On January 3, 2017, Agile Therapeutics released data from its Phase 3 SECURE study assessing its combined hormonal contraceptive patch Twirla. This study was conducted at the request of the U.S. Food and Drug Administration, which rejected Agile Therapeutic’s initial marketing application in 2013. In a Company press release, Agile Therapeutics referred to “positive top-line results” in the study, despite the fact that 1.7% of subjects experienced “serious adverse events” including “deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression.” In addition, 51.4% of subjects discontinued the study. Following this news, shares of Agile Therapeutics were down 59% on intraday trading on January 4, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.